(Q33966421)

30 July 2017

1 reference

title

Pharmacokinetics of rofecoxib: a specific cyclo-oxygenase-2 inhibitor. (English)

1 reference

30 July 2017

1 reference

Neal M Davies

1

1 reference

30 July 2017

Xiao W Teng

series ordinal

2

1 reference

30 July 2017

Neil M Skjodt

series ordinal

3

1 reference

30 July 2017

publication date

1 January 2003

1 reference

Clinical Pharmacokinetics

30 July 2017

published in

1 reference

30 July 2017

volume

42

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

545-556

1 reference

Preoperative oral rofecoxib does not decrease postoperative pain or morphine consumption in patients after radical prostatectomy: a prospective, randomized, double-blinded, placebo-controlled trial

30 July 2017

cites work

1 reference

12 December 2020

The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.

1 reference

12 December 2020

Improved procedure for the the determination of rofecoxib in human plasma involving 96-well solid-phase extraction and fluorescence detection

1 reference

12 December 2020

Inhibition of cyclooxygenase-2 attenuates urinary prostanoid excretion without affecting renal renin expression

1 reference

12 December 2020

Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles

1 reference

12 December 2020

The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs

1 reference

12 December 2020

[Topical pharmacology. COX-2 inhibitors]

1 reference

12 December 2020

The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials

1 reference

12 December 2020

Current treatment of juvenile rheumatoid arthritis.

1 reference

12 December 2020

Rofecoxib: a new selective COX-2 inhibitor.

1 reference

12 December 2020

Lack of pharmacokinetic interaction between rofecoxib and methotrexate in rheumatoid arthritis patients

1 reference

12 December 2020

Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans

1 reference

12 December 2020

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

1 reference

12 December 2020

Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients

1 reference

12 December 2020

Inhibition of COX-2 counteracts the effects of diuretics in rats

1 reference

12 December 2020

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

12 December 2020

Determination of rofecoxib, a cyclooxygenase-2 specific inhibitor, in human plasma using high-performance liquid chromatography with post-column photochemical derivatization and fluorescence detection

1 reference

12 December 2020

High performance liquid chromatographic determination of cyclooxygenase II inhibitor rofecoxib in rat and human plasma

1 reference

12 December 2020

The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects

1 reference

12 December 2020

Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial

1 reference

12 December 2020

Rofecoxib-induced renal dysfunction in a patient with compensated cirrhosis and heart failure

1 reference

12 December 2020

A rapid and sensitive high-performance liquid chromatography assay for rofecoxib in human serum.

1 reference

12 December 2020

Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans.

1 reference

12 December 2020

Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib

1 reference

12 December 2020

A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers

1 reference

12 December 2020

COX-2 inhibition and thrombotic tendency: a need for surveillance

1 reference

12 December 2020

Synthesis, characterization, and activity of metabolites derived from the cyclooxygenase-2 inhibitor rofecoxib (MK-0966, Vioxx)

1 reference

12 December 2020

COX 2 inhibitor and fulminant hepatic failure

1 reference

12 December 2020

Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice

1 reference

12 December 2020

Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty

1 reference

12 December 2020

Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques

1 reference

12 December 2020

Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

1 reference

12 December 2020

A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database

1 reference

12 December 2020

Cyclooxygenase-2 in myocardium stimulation by angiotensin-II in cultured cardiac fibroblasts and role at acute myocardial infarction

1 reference

12 December 2020

Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study

1 reference

12 December 2020

Determination of rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection

1 reference

12 December 2020

LC determination of rofecoxib in bulk and pharmaceutical formulations

1 reference

12 December 2020

Acute renal failure associated with rofecoxib

1 reference

12 December 2020

A possible interaction between lithium and rofecoxib

1 reference

12 December 2020

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

12 December 2020

Effect of rofecoxib on the antihypertensive activity of lisinopril

1 reference

12 December 2020

Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers

1 reference

12 December 2020

Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids

1 reference

12 December 2020

Role of prostacyclin in the cardiovascular response to thromboxane A2

1 reference

12 December 2020

Involvement of Human UGT2B7 and 2B15 in Rofecoxib Metabolism

1 reference

12 December 2020

The cyclooxygenase-2 inhibitors: safety and effectiveness

1 reference

12 December 2020

Effect of rofecoxib on the pharmacokinetics of chronically administered oral contraceptives in healthy female volunteers

1 reference

12 December 2020

The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery

1 reference

12 December 2020

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

1 reference

12 December 2020

10.2165/00003088-200342060-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1010480506

0 references

1 reference